AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$APVO

Aptevo Therapeutics Inc.

Price · $APVOvia TradingView
AI sentiment · 7d1 articles
MAY 22net (bullish − bearish)MAY 28
Bullish
1
Neutral
0
Bearish
0
Insider · 30dFeed →

No SEC Form 4 filings for $APVO in the last 30 days.

Top stories · $APVOMore →
MAY 27·finanznachrichten.deHigh

Aptevo Therapeutics: Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

Aptevo Therapeutics (Nasdaq:APVO) and Niowave announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Aptevo will supply multispecific targeting assets starting with Nectin-4; Niowave will provide radioisotopes and manufacturing, including Actinium-225. At closing, Niowave made an at-the-market equity investment for a 7.9% stake, potentially rising to 19.99% via warrant exercises.

MAR 27·Stock Titan

Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data

Aptevo Therapeutics (NASDAQ: APVO) detailed its bispecific cancer pipeline and clinical trial data for its lead acute myelogenous leukemia (AML) candidate, mipletamig, in its latest 10-K filing. Mipletamig, a CD123xCD3 T-cell engager, demonstrated an 86% clinical benefit rate and no cytokine release syndrome in frontline AML patients during the RAINIER trial. The company is also advancing ALG.APV-527 for solid tumors, as well as six preclinical candidates leveraging its ADAPTIR and ADAPTIR-FLEX platforms.

News on $APVO